EGFR and cancer: found that patients with EGFR/RB1/TP53-mutant lung cancers had a shorter time to discontinuation than EGFR/TP53- and EGFR-mutant-only cancers(9.5 versus 12.3 versus 36.6 months, respectively, P=2×10-9).